MedTrace Logo

A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

NCT05584644 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-12-19

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical study is to describe the patient population, breast cancer treatment, and breast cancer treatment results of adult female patients who have received palbociclib combination treatments for advanced or metastatic breast cancer in India.

There are two groups of patients this study will describe. The first group of patients will have received palbociclib in combination with aromatase inhibitor (as prescribed by the Physician) for the treatment of postmenopausal women with HR+/HER2- advanced breast cancer as initial endocrine-based therapy for their metastatic disease. The second group of patients will have received palbociclib for the treatment of hormone receptor HR+/HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy.

Conditions

  • Breast Cancer
  • Breast Carcinoma
  • Breast Neoplasms
  • Breast Tumors
  • Cancer of Breast

Interventions

DRUG

Palbociclib plus hormonal treatment - first line treatment

Palbociclib plus hormonal treatment

DRUG

Palbociclib plus hormonal treatment - second line treatment

Palbociclib plus hormonal treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2022-02-22
Completion
2022-02-22

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05584644 on ClinicalTrials.gov